Recursion is near the start of its growth story. In case you're not familiar, its business has three segments, but only two have any chance of yielding revenue in the near term. The company's ...

Recursion Pharmaceuticals RXRX is strategically leveraging its AI-powered drug discovery platform through multiple high-value collaborations, positioning itself for long-term growth and sustainability ...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Hello, everyone, and welcome to this next session on the final day of the 28th Annual Needham Growth Conference. I'm Ryan MacDonald, and I lead Needham's Healthcare Technology research efforts. And in ...

In this week’s edition of InnovationRx, we look at a new biotech fund spearheaded by Recursion, a shift in bird flu strategy from the Trump Administration, a new vaccine approval from the FDA, ...

If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both companies ...

RXRX is advancing fibrosis, oncology, and neuroscience treatments via major pharma collaborations. Deals with Bayer, Roche, Sanofi, and Merck offer multi-billion milestone and royalty opportunities.